RxDoctor Payments Data

Jeffrey Boatman

Psychiatric/Mental Health, Adult · Saint Louis, MONPI 1265570592

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 55.3% of the total. Reporting peaked in 2021 at $4,366 and has fallen 90.8% since, to $400 in 2025.

$6,904in general payments, 2019–2025

Across 126 payments — averaging $54.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Genentech USA, Inc.$750
  • Otsuka America Pharmaceutical, Inc.$648
  • Acadia Pharmaceuticals Inc$539
  • Johnson & Johnson$215
  • Neurocrine Biosciences, Inc.$185
  • plus $749 from 14 others

What the payments were for

  • Consulting fees$75011%
  • Speaking & faculty fees$3,55051%
  • Travel & lodging$130%
  • Food & beverage$2,56737%
  • Education$230%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychiatric/mental health, adult providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$78,548
Medicare patients
398
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine34$228,727
AustedoDeutetrabenazine26$32,989
Lurasidone Hcl24$9,104
Aripiprazole37$3,659
Quetiapine Fumarate138$2,713
Divalproex Sodium37$1,785
Escitalopram Oxalate191$1,654
Mirtazapine58$1,410
Duloxetine Hcl40$1,191
Buspirone Hcl88$1,090
Trazodone Hcl120$919
Medroxyprogesterone Acetate21$484
Donepezil Hcl44$473
Olanzapine31$463
Memantine Hcl ErMemantine Hcl11$414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$3,819$261,71660 claims
Lilly USA, LLCOlanzapine$55$46331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Missourion file to place this against a meaningful peer group, so we don't.

Other psychiatric/mental health, adult in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →